About
Noviota is a private biotechnology company. Privately held. Commercially focused. Internationally directed.
We design precision biological systems for medicine. The work spans human and animal health, with infectious disease as the operating focus.
Noviota develops programmable therapeutic platforms for infectious disease across human and animal health. The name is built from nov-, from the Latin nova, the new, and -iota, the closing four letters of biota, the living world. The compound also reads, independently, as the Greek letter ι — long used as a metaphor for the smallest meaningful unit. New life at the smallest meaningful scale.
The company is privately held. Noviota is a single-focus operation: the design of programmable cellular systems, the documentation infrastructure that supports them, and the commercial route to deploy them through partnerships.
What we do
The active focus is the engineering of cellular agents that can sense, decide and act inside a living organism. These are therapeutic platforms designed at the molecular scale to address infectious disease, with applications spanning human medicine, veterinary medicine and livestock health, including One Health interventions where the same pathogen crosses species.
The biology is already extraordinary. Cells navigate, communicate, distinguish self from non-self, and execute coordinated responses. What they have lacked is a design discipline: a standardised way of specifying what they should do, documenting how they were built, and verifying that the second batch behaves like the first. That is the gap we exist to close.
Why infectious disease
Antimicrobial resistance is no longer a distant warning. Pandemic preparedness is not optional. Zoonotic spillover events are accelerating. The standard pharmaceutical pipeline of twelve years and a billion dollars per molecule does not match the timescales on which new pathogens emerge.
A programmable therapeutic platform, properly designed and documented, changes the arithmetic. The chassis is built once. The targeting layer is reconfigured for the threat at hand. Delivering on this requires the design and documentation infrastructure to exist first, which is where Noviota starts.
How we operate
Noviota is a private commercial operation. The intellectual property the company generates is its principal asset. Frameworks, design representations, platform architecture and protocols are protected accordingly.
The commercial route to market is collaboration. Noviota designs and owns. Partners deliver experimental validation, manufacturing capacity, and clinical translation. We are selective about partners and the criterion is fit.
What we want to achieve
One. Establish design and documentation standards that make precision biological medicine trustworthy at scale.
Two. Develop programmable therapeutic platforms for infectious disease, configurable against specific pathogens and deployable on timescales that match the threat.
Three. Build a private company whose intellectual property and methods become a reference standard for how precision biological medicine is designed and brought to clinical use, with that reference position internationally recognised.